CYH vs LCTX

CYH exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a negative Price-to-Book ratio (-0.25), which indicates negative shareholders' equity. While the current P/E ratio appears deceptively low, the surge to a Forward P/E of 20.81 suggests a significant expected collapse in earnings. Revenue is contracting (-6.10% YoY) and the stock is in a persistent technical downtrend, losing 74% of its value over five years. The provided growth-based intrinsic value of $24.08 is fundamentally disconnected from the company's current balance sheet insolvency and should be disregarded.

LCTX exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position with a current ratio of 5.20 and low debt, it suffers from negative gross margins (-22.80%) and an unsustainable operating margin of -99.09%. The valuation is extreme, with a Price/Sales ratio of 26.70 and a PEG of 10.64, suggesting the stock is priced for perfection despite consistent earnings misses. The stark contrast between the 'Strong Buy' analyst consensus and the deterministic health scores suggests a speculative bet on clinical outcomes rather than a value-driven investment.